Glenmark Pharmaceuticals Inc., USA has announced the official launch of Vancomycin Hydrochloride for Injection USP (500 mg/vial and 1 g/vial). This new product is bioequivalent and therapeutically equivalent to the reference listed drug from Fresenius Kabi USA, LLC. The product targets a market that achieved annual sales of approximately $37.9 million for the 12-month period ending March 2026, further strengthening the company’s North American injectable portfolio.
Expanding Injectable Portfolio
On May 18, 2026, Glenmark Pharmaceuticals Inc., USA, confirmed the introduction of Vancomycin Hydrochloride for Injection USP in 500 mg and 1 g vial configurations. This launch represents a strategic step for the company in expanding its footprint within the United States, focusing on delivering high-quality and affordable treatment options to healthcare providers and patients.
Market Opportunity and Strategic Focus
The product, which serves as a therapeutic equivalent to the reference drug by Fresenius Kabi USA, LLC, enters a competitive and established market segment. According to IQVIA sales data for the year ending March 2026, the market for this injection achieved annual sales of roughly $37.9 million. Marc Kikuchi, President & Business Head for North America, stated that this launch underscores the company’s ongoing commitment to improving medicine access while reinforcing its dedicated focus on the U.S. injectable market.
Source: BSE
